Effectiveness of Benralizumab in Severe Eosinophilic Asthma Under Conditions of Routine Clinical Practice

López, JC Miralles; Espinosa, Rubén Andújar; Bravo-Gutiérrez, FJ; Castilla-Martínez, Manuel; Flores-Martín, I; Alemany-Francés, ML; Pajarón-Fernández, MJ; Gonzalez, Adrianna; Valverde-Molina, J.; Pérez‐Fernández, Virginia

doi:10.18176/jiaci.0793

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, Miralles López et al recently confirmed the efficacy of benralizumab in reducing exacerbation and eliminating the use of OCS in patients having eosinophils ≥300 cells/mm 3 regardless of BEC stratification. 32 A slightly greater reduction in exacerbations was seen in patients with BEC higher than 400 cells/mm 3 when compared with patients showing BEC between 300 and 400 cells/mm 3 in the Benralizumab Patient Access Programme (BPAP) study. 33 With regard to lung function, benralizumab was found to be more effective in improving FEV 1 in patients with BEC greater than 500 cells/mm 3 , in line with the results from this post hoc analysis.…”

Section: Discussionmentioning

confidence: 94%

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

Senna¹,

Aliani²,

Altieri³

et al. 2022

JAA

View full text Add to dashboard Cite

Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count (BEC). Patients included in real-world studies are often characterized by high mean/median BEC, while patients with BEC close to 300 cells/mm 3 are poorly represented. This post hoc analysis from the Italian study ANANKE aims to define the clinical features and corroborate the efficacy of benralizumab in real world in the BEC 300-450 cells/mm 3 subset of patients. Patients and Methods: Post hoc analysis of the Italian, multicenter, observational, retrospective real-life study ANANKE (NCT04272463). Baseline clinical and laboratory characteristics were collected in the 12 months prior to benralizumab treatment and presented for a BEC 300-450 cells/mm 3 subgroup of patients. Change over time of BEC, annualized exacerbation rate (AER), asthma control (ACT), lung function and oral corticosteroid (OCS) use at 16, 24 and 48 weeks after benralizumab introduction were collected. Results: A total of 164 patients were analyzed, 34 of whom with a BEC of 300-450 cells/mm 3 . This subgroup was more likely to be female (64.7%), with lower rates of severe exacerbations at baseline when compared to the total population (0.69 vs 1.01). After 48 weeks of benralizumab treatment, the BEC 300-450 subset showed similar reductions in AER (−94.8% vs −92.2%) and OCS use

show abstract

Section: Discussionmentioning

confidence: 94%

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

Senna¹,

Aliani²,

Altieri³

et al. 2022

JAA

View full text Add to dashboard Cite

show abstract

“…The ORBE II study, as part of the XALOC programme, is one of the largest real-world studies on benralizumab at international level and the largest one presented in Spain to date. The first real-life studies assessing the therapeutic effect of benralizumab in small SEA patient cohorts confirmed a rapid gain in asthma control and lung function, a significant reduction or elimination of exacerbations and maintenance OCS use, and a decrease in the number of ED visits [ 30 – 34 ]. More importantly, data from these studies confirmed that the improvement in all these clinical outcomes was sustained and even increased over time.…”

Section: Discussionmentioning

confidence: 99%

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study

Padilla-Galo,

Moya Carmona,

Ausín

et al. 2023

Respir Res

View full text Add to dashboard Cite

Background The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain. Methods ORBE II (NCT04648839) was an observational, retrospective cohort study in adult SEA patients who had been prescribed benralizumab. Demographic and clinical data of 204 SEA patients were collected 12 months prior to benralizumab initiation (baseline) and at follow-up. Exacerbation rate, asthma symptoms, maintenance oral corticosteroid (OCS) use and lung function were evaluated, among other variables. Results A total of 204 SEA patients were evaluated. Mean (standard deviation, SD) age of the study population was 56.4 (12.4) years, 62.3% were women and mean (SD) duration of asthma was 15.1 (12.7) years. Median (Q1–Q3) follow-up duration was 19.5 (14.2–24.2) months. At baseline, 72.6% of the overall population (OP) presented blood eosinophil counts ≥ 300 cells/µL; 36.8% had comorbid chronic rhinosinusitis with nasal polyps (CRSwNP); 84.8% reported at least one severe exacerbation, and 29.1% were OCS-dependent. At 1 year of follow-up, patients receiving benralizumab treatment had a 85.6% mean reduction in exacerbations from baseline, and 81.4% of patients achieved zero exacerbations. We also found a clinically relevant mean (SD) increase in pre-bronchodilator (BD) FEV1 of 331 (413) mL, with 66.7% of patients achieving a pre-BD FEV1 increase ≥ 100 mL, and 46.3% of patients achieving a pre-BD FEV1 ≥ 80% of predicted. Regarding symptom control, 73.8% of the OP obtained an ACT score ≥ 20 points. After 1 year of follow-up, mean reduction in the daily OCS dose was 70.5%, and complete OCS withdrawal was achieved by 52.8% of the OCS-dependent patients. Almost half (43.7%) of the OP on benralizumab met all four criteria for clinical remission. Patients with concomitant CRSwNP obtained similar or enhanced outcomes. Conclusions These data support the real-world benefits of benralizumab in SEA patients, and particularly in those with concomitant CRSwNP. Trial registration NCT04648839.

show abstract

Biologics in severe asthma – a molecular perspective

Haidar¹,

Panaitescu²

2022

Alergologia

View full text Add to dashboard Cite

Effectiveness of Benralizumab in Severe Eosinophilic Asthma Under Conditions of Routine Clinical Practice

Cited by 4 publications

References 0 publications

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study

Biologics in severe asthma – a molecular perspective

Contact Info

Product

Resources

About